CD8A and neoplasm: Recently, Ahmad and colleagues described CD4+ and CD8+ PD-L2-specific T cells, which can directly exert cytotoxic activity against PD-L2-expressing target cells and indirectly release pro-inflammatory cytokines into the tumor microenvironment, indicating the possibility of novel PD-L2-based vaccines complementary to checkpoint inhibitors.